Table 2.

Change in Total Symptom and Individual Symptom Relief Score of a 4-Week Drug Administration

Modified intention-to-treat analysis	Change in frequency				Change in severity
	Mosapride CR (n = 54)	Nortriptyline (n = 50)	P-value		Mosapride CR (n = 54)	Nortriptyline (n = 50)	P-value
Total symptom score change	–7.4 ± 7.1	–8.9 ± 7.1	0.149		–7.6 ± 7.0	8.1 ± 7.2	0.787
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Dyspepsia symptoms
Early satiety	–0.6 ± 1.3	–0.9 ± 1.4	0.249		–0.7 ± 1.2	–0.8 ± 1.3	0.530
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Postprandial fullness or discomfort	–1.0 ± 1.2	–1.3 ± 1.4	0.350		–1.0 ± 1.1	–1.3 ± 1.2	0.289
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Epigastric bloating	–1.1 ± 1.3	–1.2 ± 1.4	> 0.999		–1.0 ± 1.0	–0.9 ±1.2	0.656
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Epigastric pain or soreness	–0.8 ± 1.2	–0.9 ±1.2	0.773		–0.8 ± 1.1	–0.7 ± 1.0	0.588
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Nausea	–0.4 ± 0.7	–0.5 ± 0.8	0.822		–0.5 ± 1.0	–0.6 ± 1.0	0.977
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Vomiting	–0.2 ± 0.6	–0.1 ± 0.3	0.828		0.2 ± 0.7	–0.1 ± 0.5	0.797
P-value	0.140	0.030			0.120	0.190
Belching	–0.7 ± 1.3	–1.0 ± 1.5	0.159		–0.7 ± 1.0	–0.9 ± 1.1	0.142
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Gastroesophageal reflux disease symptoms
Heartburn	–0.9 ± 1.0	–0.9 ± 1.2	0.921		–1.0 ± 1.1	–1.0 ± 1.3	0.898
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Retrosternal chest pain or discomfort	–0.8 ± 1.1	–0.8 ± 1.2	0.787		–0.8 ± 1.2	–0.7 ± 1.1	0.540
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Acid reflux	–0.5 ± 1.0	–0.5 ±0.9	0.819		–0.5 ± 1.0	–0.5 ± 0.8	0.883
P-value	< 0.001	< 0.001			< 0.001	< 0.001
Regurgitation	–0.4 ± 0.9	–0.7 ± 1.1	0.154		–0.4 ± 1.0	–0.5 ± 1.1	0.820
P-value	0.003	< 0.001			0.003	0.001

CR, controlled-release.

Data are presented as mean ± SD.